Lesaffre completes Gnosis acquisition

December 13, 2018

Three years after becoming a majority shareholder in Gnosis, Lesaffre has fully acquired the Italian biotechnology company.

Three years after becoming a majority shareholder in Gnosis (Desio, Italy), Lesaffre (Marcq-en-Baroeul, France) has fully acquired the Italian biotechnology company. Both firms specialize in yeast and fermentation for use in nutraceutical and cosmetic applications.

“For the past three years, we have developed cooperation between Lesaffre and Gnosis teams to become today a unique provider of products and services that are increasingly innovative and closely address our customers’ needs in the nutrition and health sectors,” said Antoine Baule, CEO of Lesaffre, in a press release.

Lesaffre is combining Gnosis with its Lesaffre Human Care business unit to offer a unified range of products and services. Lesaffre Human Care develops and supplies a number of ingredients, including nutritional and fortified yeasts, yeast fractions, probiotic yeasts and bacteria, and pure molecules for wide range of applications such as digestive health, immune health, joint health, liver health, women’s health, and personal care.

“Developing Gnosis has been an exciting challenge,” said Renzo Berna, former CEO of Gnosis, in a press release. “After 25 years, Gnosis has become a reference on the market able to design and manufacture fermentation purified metabolites as healthcare active ingredients for the nutraceutical and pharmaceutical markets. I am convinced that Lesaffre, a family group known and recognized internationally for its professionalism and the quality of its products and services, will take this company even further forward.”